FDA
-
-
-
-
-
-
-
VBI Vaccines (VBI) to Sell IP Rights for VBI-2601 to Brii Biosciences
-
-
-
-
-
-
-
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
-
-
-
-
-
-
-
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
VBI Vaccines (VBIV) Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
-
-
-
-
-
-
-
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
-
-
-
-
-
-
-
VBI Vaccines (VBIV) Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
-
-
-
-
-
-
-
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

